CureVac Establishes U.S. Operations
News Sep 15, 2015
Headquartered in Tϋbingen, Germany, where CureVac was founded in 2000 as a spinoff of the University, the expansion into the U.S. extends the company’s footprint into one of the world’s preeminent biotechnology hubs. The US subsidiary will be headed by Karen Slobod, MD, as managing director, formerly Head of the Maternal Immunization Franchise at Novartis Vaccines, and will primarily focus on development activities involving CureVac’s rapidly growing pipeline of mRNA-based prophylactic vaccines, which include programs targeting Rotavirus, RSV, HIV, and influenza virus in collaborations with the Bill & Melinda Gates Foundation, IAVI and Johnson & Johnson. Additionally, the U.S. operations will enable CureVac to more directly engage the U.S. pharmaceutical and investor communities.
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, commented, “Expansion into the U.S. is an important step in CureVac’s corporate and clinical growth as it will enable us to capitalize on the numerous research and business opportunities related to our industry-leading mRNA technology platform. As such our U.S. office will provide an important base for CureVac to extend our U.S. interest, while enhancing our development capabilities, particularly those targeting mRNA-based prophylactic vaccines.”
CureVac’s technology utilizes natural, chemically unmodified mRNA to develop a broad range of therapeutic candidates in cancer immunotherapies and prophylactic vaccines as well as molecular therapy. To date, CureVac has validated its approach in numerous clinical trials, including an ongoing Phase IIb study in prostate cancer. A recent study demonstrated that CureVac’s mRNAs are also able to raise relevant protein levels without stimulating an unwanted immune reaction and achieved meaningful biological responses.
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.